Exploratory Study on Nanoparticle Co-Delivery of Temozolomide and Ligustilide for Enhanced Brain Tumor Therapy
Pharmaceutics · 04.02.2025 · 17 (2) · 191
DOI: 10.3390/pharmaceutics17020191 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 04.02.2025. Verfasst von Gang Ke und 9 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Modern Preparation of Traditional Chinese Medicine, Ministry of Education, Jiangxi University of Chinese Medicine, Nanchang 330004,…. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Chinese Medicine Preparation Technology and Equipment Innovation Team of the Jiangxi Uni-versity of Chinese Medicine, Innovation Project for College Students in Jiangxi University of Chinese Medicine.
Abstract (Originalsprache)
Background
Temozolomide (TMZ) is the first-line therapy for glioblastoma (GBM), but its clinical efficacy is limited by its short half-life, poor brain targeting, adverse side effects, and the development of drug resistance. Ligustilide (LIG) has been shown to enhance blood-brain barrier permeability and reduce P-glycoprotein activity, thereby potentiating the synergistic effect of TMZ against GBM.
Methods
The dual-drug-loaded nanoparticles encapsulating both TMZ and LIG (TMZ/LIG-NPs) were prepared using Poly (d,l-lactic-co-glycolide)-monomethoxy poly (ethylene glycol) (PLGA-mPEG). The physicochemical properties of the NPs, including particle size and zeta potential, were characterized. Cellular uptake of NPs was evaluated using flow cytometry and fluorescence staining. The pharmacokinetic profile and cytotoxicity of TMZ/LIG-NPs were compared to those of free TMZ and a mixture of TMZ and LIG in rat and glioma cells, respectively.
Results
The mean particle size of TMZ/LIG-NPs was 117.6 ± 0.7 nm, with a zeta potential of −26.5 ± 0.4 mV. Cellular uptake of NPs was significantly higher than that of free drug in U251 cells. Encapsulation of TMZ in NPs significantly increased its half-life by 1.62-fold compared to free TMZ and significantly improved its pharmacokinetic profile. Moreover, the storage stability of the TMZ/LIG-NPs solution was extended to one month. The toxicity of TMZ/LIG-NPs to glioma cells C6 and U251 was markedly enhanced compared to the mixture of TMZ and LIG.
Conclusions
The development of TMZ/LIG-NPs using PLGA-mPEG effectively enhanced the stability and efficacy of both TMZ and LIG. This dual drug-loaded nanoparticle system represents a promising strategy for glioblastoma therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Key Laboratory of Modern Preparation of Traditional Chinese Medicine, Ministry of Education, Jiangxi University of Chinese Medicine, Nanchang 330004, China.
- Luzhou People's Hospital, Luzhou 646000, China.
- School of Life Science, Advanced Research Institute of Multidisciplinary Science, School of Medical Technology, Key Laboratory of Molecular Medicine and Biotherapy, Key Laboratory of Medical Molecule Science and Pharmac…
ORCID-Profile: Jing Zhang
Förderung
- National Natural Science Foundation of China
- Chinese Medicine Preparation Technology and Equipment Innovation Team of the Jiangxi Uni-versity of Chinese Medicine
- Innovation Project for College Students in Jiangxi University of Chinese Medicine
- Chinese Medicine Preparation Technology and Equipment Innovation Team of the Jiangxi University of Chinese Medicine
Zitieren
APA
Ke, G., Zhang, M., Hu, P., Zhang, J., Naeem, A., Wang, L., Xu, H., Liu, Y., Cao, M., & Zheng, Q. (2025). Exploratory Study on Nanoparticle Co-Delivery of Temozolomide and Ligustilide for Enhanced Brain Tumor Therapy. Pharmaceutics, 17(2), 191. https://doi.org/10.3390/pharmaceutics17020191
Vancouver
Ke G, Zhang M, Hu P, Zhang J, Naeem A, Wang L, et al. Exploratory Study on Nanoparticle Co-Delivery of Temozolomide and Ligustilide for Enhanced Brain Tumor Therapy. Pharmaceutics. 2025;17(2):191. doi:10.3390/pharmaceutics17020191
BibTeX
@article{Ke2025,
author = {Ke, Gang and Zhang, Mingxia and Hu, Pengyi and Zhang, Jing and Naeem, Abid and Wang, Lianfang and Xu, Huixin and Liu, Yu and Cao, Ming and Zheng, Qin},
title = {Exploratory Study on Nanoparticle Co-Delivery of Temozolomide and Ligustilide for Enhanced Brain Tumor Therapy},
journal = {Pharmaceutics},
year = {2025},
volume = {17},
number = {2},
pages = {191},
doi = {10.3390/pharmaceutics17020191}
}
EUVIMED